Eosinophil-Driven Diseases (EDDs)电竞外围投注app

LOL外围

Our commitment to eosinophil-driven diseasesLOL外围

电竞外围投注app

EDDs are inflammatory illnesses in which elevated eosinophils are a direct cause or are thought to play a critical role.1 Some EDDs have limited or no approved treatment options, creating a significant unmet need for innovative medicines. We know now that a process called eosinophilic immune dysfunction may be responsible for the eosinophil recruitment and activation that is driving these diseases. Backed by a growing body of evidence, we’re committed to advancing the understanding of the role of eosinophils in inflammatory diseases across Respiratory & Immunology电竞外围投注app

 


LOL外围



LOL外围

电竞外围投注app












LOL外围


At AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. Join us and help deliver life-changing medicines. Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals. 
电竞外围投注app




References

1. American Partnership for Eosinophilic Disorders. What is an eosinophil associated disease? Available at: https://apfed.org/关于-ead/what-is-an-eosinophil-associated-disease/. [Last accessed: September 2019].

2. Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018; 9095275.

3. American Academy of Allergy Asthma & Immunology. Atopic dermatitis. Available at:https://www.aaaai.org/conditions-and-treatments/library/allergy-library/eczema-atopic-dermatitis[Last accessed: April 2020].

4. National Organisation for Rare Disorders. Bullous Pemphigoid. Available at: https://rarediseases.org/rare-diseases/bullous-pemphigoid/. [Last accessed: April 2020].

5. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. [Online]. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf [Last accessed: April 2020].

6. Adeloye D, Chua S, Lee C, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415.

7. Saha S and Brightling SE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(1):39-47.

8. American Academy of Allergy Asthma & Immunology. Hives (urticaria) and Angioedema overview Available at: https://www.aaaai.org/conditions-and-treatments/library/allergy-library/hives-angioedema. [Last accessed: January 2020].

9. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–2016. doi: 10.1111/all.13209.

10. Wenzel SE. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172:149-160.

11. Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Rev Respir Med. 2016;10(10): 1093-1103.

12. Trivedi SG, Lloyd CM. Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci. 2007;64(10):1269-1289.

13. American Partnership for Eosinophilic Disorders. EoE. Available at: https://apfed.org/关于-ead/egids/eoe/. [Last accessed: September 2019].

14. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Available at: https: apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/. [Last accessed: September 2019].

15. Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010; 36: 527-543.

16. American Partnership for Eosinophilic Disorders. Hypereosinophilic Syndromes. Available at: https://apfed.org/关于-ead/hypereosinophilic-syndrome/. [Last accessed: September 2019].

17. American Academy of Allergy Asthma & Immunology. Nasal Polyps. Available at: https://aaaai.org/conditions-and-treatments/conditions-dictionary/Nasal-Polyps. [Last accessed: September 2019].

 


              Veeva ID: Z4-23707

              Date of Preparation: April 2020

              Date of Expiration: April 2022